In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients.
Mohan Bangalore
Senior Director and Site Head, Wyeth
In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients. While at GlaxoSmithKline, I helped set up oncology clinical trials in India and China for Tykerb (lapatinib), which is now on the market for treatment of breast cancer. It was gratifying to see the drug I worked on help cancer patients. That moment was decisive, as it exemplifies our ability to improve patients' lives. The experience also opened the door for me to India and China clinical operations.
My major accomplishment at Wyeth has been the establishment of the India Clinical Research Center (ICRC) in Bangalore, through a novel partnership with Accenture. Today, ICRC has some 160 team members supporting core clinical functions such as clinical writing, statistical programming, medical research support, document quality, document technology, and clinical administrative data support. I also provide administrative and operational oversight for ICRC, and identify opportunities across functions and develop strategic solutions with stakeholders.
I look forward to developing new outsourcing models and creating innovative ways for sponsors and service providers to collaborate. One thing I know is that I will continue to make significant contributions to global clinical operations in the pharmaceutical industry. I see myself becoming an industry leader in clinical outsourcing with a special focus on India and China clinical operations.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.